BridgeMD
Tests treatment safety and results for Hematological Malignancies
Official title Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies
ClinicalTrials.gov ID: NCT06150469
What this study is testing
What is "Blend of ginger and lemon essential oils", "Neutral oil"?
"Blend of ginger and lemon essential oils", "Neutral oil" is an investigational medicine, given as an inhaled treatment, being studied as a potential treatment for hematological malignancies.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This project will optimise the management of chemotherapy-induced nausea and vomiting, with improvements in nausea and vomiting scores, quality of life and appetite expected in participants benefiting from the intervention. In all cases, the use of complementary methods is recommended and improves the management of people with cancer because they offer a person-centred approach.
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients aged over 18 years,
- Chemo-naive patients at inclusion,
- Patients with haematological malignancies treated treated with chemotherapy,
- Patients physically and mentally able to use the aromastick,
- Patients who speak, read and write French,
You likely can't join if
- Asthmatic patients.
- Patients with anosmia.
- Patients allergic to EO, lemon or ginger.
- Patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting,
- Patients practising herbal medicine or acupuncture,
- Pregnant and breast-feeding women,
See the full eligibility criteria
- Patients aged over 18 years,
- Chemo-naive patients at inclusion,
- Patients with haematological malignancies treated treated with chemotherapy,
- Patients physically and mentally able to use the aromastick,
- Patients who speak, read and write French,
- Patients who have given signed consent,
- Patients with social security cover.
- Asthmatic patients.
- Patients with anosmia.
- Patients allergic to EO, lemon or ginger.
- Patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting,
- Patients practising herbal medicine or acupuncture,
- Pregnant and breast-feeding women,
- Patients under guardianship, tutorship or curatorship,
- Patients taking part in treatment studies involving antiemetic drugs or nutritional products,
- Patients who have already had cancer.
The study team makes the final eligibility decision.
Where it's taking place
- Brivé, France
- La Réunion, France
- Limoges, France
- Saint-Germain-en-Laye, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brivé, France; La Réunion, France; Limoges, France; Saint-Germain-en-Laye, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.